In recent years, glucagon-like peptide 1 receptor agonists — more commonly known as GLP-1 medications — have dominated headlines for their success in managing blood sugar levels and significantly reducing weight.

However, a new study shows GLP-1s could have another benefit: treating migraines.

In a new pilot study presented at the European Academy of Neurology Congress, results showed that after taking GLP-1s, people who suffer from migraines reduced the number of days per month with symptoms by almost half.

The study included 31 adults — 26 women and five men — with a median age of 44, all of whom reported experiencing headaches about 20 days each month. For 12 weeks, participants received daily injections of liraglutide (Saxenda). All also met the criteria for obesity and continued ta

See Full Page